National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Atezolizumab (Tecentriq®) in combination with carboplatin and etoposide for 1L ES-SCLC HTA ID: 19030

Atezolizumab (Tecentriq®) in combination with carboplatin and etoposide is indicated for first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

NCPE Assessment Process Complete
Rapid Review commissioned: 19/08/2019
Rapid Review completed 16/09/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 18/09/2019
Pre-submission consultation with Applicant 16/12/2019
Submission received from Applicant 08/05/2020
Preliminary review sent to Applicant 19/06/2020
NCPE assessment re-commenced 17/07/2020
Preliminary review follow-up sent to Applicant 31/07/2020
NCPE assessment re-commenced 04/08/2020
Factual accuracy check sent to Applicant 04/09/2020
NCPE assessment re-commenced 11/09/2020
NCPE assessment completed 24/09/2020
NCPE assessment outcome The NCPE recommends that atezolizumab in combination with carboplatin and etoposide for the first-line treatment of adult patients with ES-SCLC is not considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

 

The HSE has approved reimbursement following confidential price negotiations March 2022.